Parallelly, a mutation in the Cytochrome P450 Family 2 Subfamily U member 1 (SPG56/CYP2U1) at 4q25 leads to early onset of spasticity in the lower body parts, aiding in walking disabilities by inhibiting the P450 hydroxylase enzyme activities, causing loss of protein structure, leading to ataxia, retina impairment, and neuropathy [64]. This evidence concerns the gene CYP2U1 and neuropathy.